caa a22 4500 445314095 CHVBK 20180317142640.0 cr unu---uuuuu 170323e20110201xx s 000 0 eng 10.1007/s11095-010-0214-7 doi (NATIONALLICENCE)springer-10.1007/s11095-010-0214-7 Nanotechnology-Based Cancer Therapeutics—Promise and Challenge—Lessons Learned Through the NCI Alliance for Nanotechnology in Cancer [Elektronische Daten] [Dorothy Farrell, Krzysztof Ptak, Nicholas Panaro, Piotr Grodzinski] ABSTRACT: The new generation of nanotechnology-based drug formulations is challenging the accepted ways of cancer treatment. Multi-functional nanomaterial constructs have the capability to be delivered directly to the tumor site and eradicate cancer cells selectively, while sparing healthy cells. Tailoring of the nano-construct design can result in enhanced drug efficacy at lower doses as compared to free drug treatment, wider therapeutic window, and lower side effects. Nanoparticle carriers can also address several drug delivery problems which could not be effectively solved in the past and include reduction of multi-drug resistance effects, delivery of siRNA, and penetration of the blood-brain-barrier. Although challenges in understanding toxicity, biodistribution, and paving an effective regulatory path must be met, nanoscale devices carry a formidable promise to change ways cancer is diagnosed and treated. This article summarizes current developments in nanotechnology-based drug delivery and discusses path forward in this field. The discussion is done in context of research and development occurring within the NCI Alliance for Nanotechnology in Cancer program. US Government, 2010 drug delivery nationallicence multi-functional nanoparticle carriers nationallicence nanoparticle nationallicence toxicity nationallicence Farrell Dorothy Center for Strategic Scientific Initiatives, Office of the Director, National Cancer Institute, NIH, 20892, Bethesda, Maryland, USA aut Ptak Krzysztof Center for Strategic Scientific Initiatives, Office of the Director, National Cancer Institute, NIH, 20892, Bethesda, Maryland, USA aut Panaro Nicholas Nanotechnology Characterization Laboratory Advanced Technology Program, SAIC-Frederick Inc., NCI-Frederick, 21702, Frederick, Maryland, USA aut Grodzinski Piotr Center for Strategic Scientific Initiatives, Office of the Director, National Cancer Institute, NIH, 20892, Bethesda, Maryland, USA aut Pharmaceutical Research Springer US; http://www.springer-ny.com 28/2(2011-02-01), 273-278 0724-8741 28:2<273 2011 28 11095 https://doi.org/10.1007/s11095-010-0214-7 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11095-010-0214-7 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Farrell Dorothy Center for Strategic Scientific Initiatives, Office of the Director, National Cancer Institute, NIH, 20892, Bethesda, Maryland, USA aut NATIONALLICENCE 700 1- Ptak Krzysztof Center for Strategic Scientific Initiatives, Office of the Director, National Cancer Institute, NIH, 20892, Bethesda, Maryland, USA aut NATIONALLICENCE 700 1- Panaro Nicholas Nanotechnology Characterization Laboratory Advanced Technology Program, SAIC-Frederick Inc., NCI-Frederick, 21702, Frederick, Maryland, USA aut NATIONALLICENCE 700 1- Grodzinski Piotr Center for Strategic Scientific Initiatives, Office of the Director, National Cancer Institute, NIH, 20892, Bethesda, Maryland, USA aut NATIONALLICENCE 773 0- Pharmaceutical Research Springer US; http://www.springer-ny.com 28/2(2011-02-01), 273-278 0724-8741 28:2<273 2011 28 11095 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer